International Stem Cell Corporation Blog: Part 4: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

Monday, August 22, 2011

Part 4: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

Ellis Martin of The Ellis Martin Report interviews Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease. http://www.ellismartinreport.com Contact: martinreports@gmail.com. International Stem Cell is a paid sponsor of The Ellis Martin Report

International Stem Cell Corporation's Objectives

1. To create an abundant source of stem cells to meet the rapidly growing research and therapeutic demands of regenerative medicine.

2. To create stem cell lines from unfertilized eggs, which would have all the benefits of human embryonic stem cells, but are superior in their ability to eliminate or diminish immune rejection in the patient.

3. To create a methodology to “cross match” stem cells for transplant into individual patients and to build a true “Cell Bank” allowing for on-demand delivery of cells that could be matched to the patient’s own immune system and reduce or eliminate the need for immunosuppressant drugs.

Forward Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

-30-

Monday, August 22, 2011

Part 4: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

ShareThis

Visit ISCO, LLCT and LLSC Websites

ISCO Mobile App QR

Subscribe here to have this info delivered to you

International Stem Cell Corporation Company Profile

International Stem Cell Corporation's Fan Box

Ben's Stem Cell News

Are You Pro Stem Cell Research?

Like this?

Check out the GEN Blog

Networked Blogs

We Blog Alot

ClickTale

ontoplist

hotvsnot

Add International Stem Cell Corporation news to your RSS reader

Subscribe, Visit or Listen to ISCO's New Podcast Below

Translate This Blog

Feed Shark

Blog Archive

International Stem Cell Corporation's Objectives

Forward Looking Statements